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For personalSummary Background/Objective: The number of gastric cancer and type II diabetes mellitus
is increasing in Korea. Metabolic surgery could be extended to gastric cancer patients with type
II diabetes, especially those who are expected to achieve long-term survival. This study aimed
to investigate change of diabetic status in patients undergoing long-limb Roux-en-Y bypass
reconstruction compared with conventional Billroth II after curative gastrectomy. In total,
130 patients from five university hospital centers underwent long-limb Roux-en Y reconstruc-
tion after radical distal gastrectomy.
Methods: In the long-limb group, the length of biliopancreatic limbs was more than 80 cm, and
the length of the Roux limb was more than 80 cm. The control group comprised 96 patients who
underwent conventional Billroth II reconstruction after distal gastrectomy. Follow-up data at
three, six, nine, and 12 months were compared between the two groups.
Results: Fasting blood sugar (FBS) and hemoglobin (Hb) A1c levels decreased more significantly
in the long-limb Roux-en-Y group (FBS: 28.8 mg/dL; HbA1c: 0.72%). However, decreases in
body mass index, albumin, and hemoglobin did not differ significantly between the two groups.
Diabetes control significantly improved in the long-limb group. In multivariate analysis, long-
limb bypass reconstruction was the significant factor for glycemic outcomes.t of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro,
rea. Fax: þ82 2 3462 5994.
.H. Choi).
.03.018
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For personal usConclusion: Roux-en-Y bypass with increased length of limbs after gastrectomy shows a favor-
able glycemic control for gastric cancer patients with type II diabetes without nutritional
deficit and anemia. To obtain future perspectives, large-scale prospective studies with long-
term outcomes are needed.
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creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The number of patients with gastric cancer and type II
diabetes mellitus (DM) is increasing, especially in Asian
people, who develop type II DM at a younger age with a
lesser degree of obesity, tend to experience complications
and die earlier.1,2 It has been demonstrated that metabolic
surgery resolves type II DM in morbidly obese patients and it
is possible that this treatment can be applied to non-
morbidly obese patients.
The basic mechanisms of metabolic surgery are insulin
sensitivity and beta cell secretory function improvements.
Proximal small intestinal bypass and/or early arrival of
chime are considered major contributing factors for
metabolic effects, and this phenomenon might be appli-
cable to gastric cancer patients.3
However, drug discontinuation rates of DM patients after
gastric surgery with conventional reconstruction are rela-
tively low.4,5 Patients with type II DM and gastric cancer are
frequently old, non-obese, and often have severely dete-
riorated pancreatic b-cell function and relatively low body
weight. To enhance the metabolic effect, increased length
of the Roux limb and/or biliopancreatic limb have been
tried. But there are few relevant studies of gastric cancer
patients with type II DM.
This study aimed to investigate change of diabetic status
in patients undergoing long-limb bypass reconstruction
after curative gastrectomy.
2. Materials and Methods
A total of 226 patients at five university hospital centers
were retrospectively enrolled. The study group comprised
130 patients who underwent radical subtotal gastrectomy
with long-limb Roux-en-Y bypass reconstruction. A control
group of 96 patients underwent Billroth II reconstruction.
One-year laboratory follow-up data were recorded for all
patients, including fasting blood sugar (FBS) and hemoglo-
bin (Hb) A1c levels. Outcomes for glycemic control,
including antidiabetic medication and insulin treatment,
were assessed. This retrospective study was approved by
the Institutional Review Board of Korea University Ansan
Hospital (IRB number AS17069).
2.1. Surgical methods
Curative subtotal gastrectomy with D1þ or D2 lymphade-
nectomy was performed for all patients. In subtotal gas-
trectomy, about 70 percent of the distal stomach isser (n/a) at Yonsei University College of M
e only. No other uses without permission. Cresected, and intestinal continuity is maintained via gas-
trojejunal reconstruction. After gastric resection, Roux-en-
Y gastrojejunostomy was performed for the long-limb
group, and Billroth II was performed for the control
group. For the long-limb group, biliopancreatic limb length
was 80e100 cm, and Roux limb length was 80e100 cm, for a
total bypass length of 160e200 cm. For the conventional
group, Billroth II reconstruction was performed for intesti-
nal continuity, with a 20e30 cm length of the afferent limb.
2.2. Analytical methods
Baseline clinical data collected to evaluate metabolic
outcomes were age, sex, preoperative diabetes control
method, diabetes duration (year), and body mass index
(BMI). Outcome measurements for diabetes control were
FBS and HbA1c levels, which were measured at three, six,
and nine months and one year postoperatively. Nutritional
profiles of BMI and HbA1c and albumin levels were also
measured at three, six, and nine months and one year
postoperatively.
Diabetes resolution and improvement were evaluated
following American Diabetes Association criteria.6 Com-
plete remission was defined as FBS level <100 mg/dL and
HbA1c level <6.0% for one year without use of antidiabetic
medication. Partial remission was defined as FBS level
100e125 mg/dL and HbA1c level <6.5% for one year in the
absence of antidiabetic medication. The improved group
included patients with type II diabetes who showed partial
or complete diabetes remission and those with reduced
antidiabetic medication dosages or decreased HbA1c and
FBS levels without increasing antidiabetic medication
dosage. Additional preoperative clinical factors of age, sex,
diabetes duration, FBS level, and BMI were compared and
analyzed as diabetes control factors.
2.3. Statistical analysis
We provided descriptive statistics of patient characteristics
in two groups and compared the baseline characteristics
between groups using c2 test for categorical data and t-test
for continuous data. Means and 95% confidence intervals of
clinical indices of FBS, HbA1c, BMI, and albumin level were
calculated preoperatively and at three, six, and nine
months and one year postoperatively. The generalized
estimating equation (GEE) model was used to estimate the
surgical effect on the clinical indices, including FBS and
HBA1c levels, over time after adjustment for age, sex, and
diabetes duration at baseline.7 Glycemic outcomes one
year after surgery were compared between groups usingedicine from ClinicalKey.com by Elsevier on February 18, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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comes were calculated in accordance with surgery type,
age, sex, diabetes duration, and preoperative clinical
indices in both univariate and multivariate models. All
statistical analyses were conducted using SAS ver.9.4 (SAS
Institute Inc., Cary, NC, USA). Statistical significance was
considered at p-values <0.05.3. Results
3.1. Clinical data variations in metabolic outcomes
by surgery type
Preoperative clinical data showed no significant differ-
ences in sex, age, diabetes duration, diabetes control,
BMI, HbA1c level, or FBS level between the two groups
(Table 1). Time and treatment effects for change in FBS
and HbA1c from baseline using the GEE are described in
Table 2. Change in FBS was 2.4 mg/dL lower in the long-
limb surgery group than in the conventional surgery
group over a one-month period. Likewise, decrease in
HbA1c was 0.06% greater in the long-limb surgery group
compared with that in the conventional surgery group at
one month. Differences in FBS and HbA1c between the
long-limb and conventional surgery groups were esti-
mated at 28.8 mg/dL and 0.72% at 12 months, respec-
tively (Table 2).
Three, six, and nine months and one year after surgery,
the mean FBS and HbA1c levels in the long-limb group
decreased more significantly than those in the conven-
tional Billroth II group (Fig. 1a, b). However, nutritional
profiles, such as HbA1c level, BMI reduction, and albumin
level were not significantly different between the two
groups (Fig. 2a, b, c).Table 1 General characteristics of patients by surgery type.
Conventional Billroth
n (%)
Total (n) 96
Sex
Man 71 (74.0)
Woman 25 (26.0)
Diabetes duration
Missing 11 (11.5)
0e9 years 55 (57.3)
10 years 30 (31.3)
Preoperative diabetes medication
no medication 4 (4.2)
oral medication 87 (90.6)
Insulin injection 5 (5.2)
mean (SD)
Age 62.8 (9.5)
Preoperative HbA1c (kg/m2) 7.2 (1.3)
Preoperative FBS (mg/dL) 145.3 (46.8)
Preoperative BMI (kg/m2) 25.3 (4.1)
Downloaded for Anonymous User (n/a) at Yonsei University College o
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Regarding diabetes remissions, there was only one partial and
no complete remission in the conventional Billroth II group.
However, in the long-limb group, four patients (3.1%) had
partial remission, and 11 patients (8.5%) had complete
remission. Diabetes control improvement was significantly
different between the two groups as measured by glycemic
control outcomes one year after surgery (Table 3). In multi-
variate analysis for glycemic outcomes during 12months after
surgery, long-limb bypass reconstruction was the only signifi-
cant factor for diabetes control improvement (Table 4).4. Discussion
Bariatric surgery was developed as a weight-loss operation
for treatment of morbid obesity. However, bariatric surgery
can not only reduce body mass, but also ameliorate obesity-
related complications, suggesting that surgery is the most
effective therapeutic option for diabetes patients with se-
vere obesity.8e10 Recent international guidelines recom-
mend surgery for type II diabetes patients with class II or III
obesity (BMI >35 kg/m2) or class I obesity with poorly
controlled hyperglycemia despite appropriate lifestyle and
pharmacological therapy.11
The number of patients with gastric cancer and type II
DM has increased, especially among Asians, who develop
type II DM at a younger age with a lesser degree of obesity,
tend to experience complications, and die earlier.1,2 For
this reason, development of reconstruction methods to
help control diabetes after gastrectomy has significant
implications for gastric cancer treatment.
It is well known that, after gastrectomy for gastric
cancer with type II DM, glucose control improves. However,II Long-limb
Roux-en Y
Chi-X2 p-value
n (%)
130
104 (80.0) 0.2828
26 (20.0)
10 (7.7) 0.6158
76 (58.5)
44 (33.9)
3 (2.3) 0.7275
120 (92.3)
7 (5.4)
mean (SD) T-test p-value
63.3 (8.9) 0.6653
7.3 (1.4) 0.8664
153.8 (61.8) 0.2437
25.8 (3.7) 0.302
f Medicine from ClinicalKey.com by Elsevier on February 18, 2020.
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Table 2 Generalized estimating equation models for fasting blood glucose, HbA1c according to surgery type.
Fasting blood sugar HbA1c
Estimate (95% CI) p-value Estimate (95% CI) p-value
Observation time (month) 0.965 (2.272e0.341) 0.148 0.031 (0.056w0.005) 0.020
Surgery type
Conventional Billroth II Reference e Reference e
Long-limb Roux-en Y 10.025 (7.557e27.608) 0.264 0.100 (0.264e0.465) 0.590
Observation time & treatment method
Observation time & conventional Reference e Reference e
Observation time & Long-limb 2.432 (4.239w0.625) 0.008 0.064 (0.100w0.028) 0.001
Sex
Women Reference e Reference e
Men 0.106 (12.110e11.897) 0.986 0.134 (0.461e0.193) 0.423
Age (year) 0.261 (0.799e0.277) 0.342 0.012 (0.026e0.002) 0.102
Diabetes duration
0e9 yrs Reference e Reference e
10 yrs 8.147 (4.083e20.376) 0.192 0.253 (0.054e0.559) 0.106
Missing 5.768 (18.804e7.268) 0.386 0.104 (0.502e0.293) 0.607
Figure 1 At the preoperative and postoperative 3, 6, 9 and
12 months levels of fasting blood sugar and Hemoglobin A1C
(mean  standard error). (a) Fasting blood sugar (mg/dL), (b)
Hemoglobin A1C (%).
300 J.-H. Kim et al.drug discontinuation rates after gastric surgery are
reportedly lower than those after bariatric surgery.3,5,12e15
Such outcomes were dependent on preoperative diabetes
duration and weight reduction.12 Also, diabetes improve-
ment was dependent on reconstruction method, and Bill-
roth II and Roux-en-Y gastrojejunal bypass reconstruction
produced better outcomes than Billroth I gastroduodenal
reconstruction.13,15 However, some reports stress that total
gastrectomy, rather than the reconstruction method, can
offer superior outcomes in diabetes improvement,14 and
glycemic outcome is reportedly significantly correlated
with BMI reduction ratio but not surgery type.5 As a result,
the effect of reconstruction method on glycemic control in
gastric cancer patients with type II DM remains
controversial.
Roux-en-Y gastric bypass is the most common procedure
for bariatric surgery to improve type II DM. The Roux-en-Y
bypass includes the gastric upper pouch, the alimentary or
“Roux” limb, the biliopancreatic limb or afferent limb, and
common limb, although there is no consensus on the
optimal length of limbs. Kim et al. suggested that
increasing the lengths of the alimentary and biliopancreatic
limbs enhances glucose control after gastrectomy for
gastric cancer and type II DM.16 Other reports support this
suggestion,17,18 although they suffer from limitations due to
small numbers of patients or applicability of the results to
the period immediately after surgery.
Regarding metabolic surgery, type II diabetes remission
can occur after gastric cancer surgery, and the basic
mechanism is entero-insular axis modification.19e21 This
procedure involves altered glucose metabolism owing to
different gut hormones, such as incretins, especially
glucagon-like peptide-1.19,21,22
Recently, the incidence of early gastric cancer has
increased in Korea,23 so there is increased possibility that
patients with gastric cancer and type II DM will achieve
long-term survival. Onco-metabolic surgery is based on the
hypothesis that modifying the traditional surgery in pa-
tients with gastric cancer and type II DM will improve
glucose control.Downloaded for Anonymous User (n/a) at Yonsei University College of M
For personal use only. No other uses without permission. CWe therefore designed an onco-metabolic surgical
concept for early gastric cancer patients with type II dia-
betes and performed Roux-en-Y anastomosis with longer
intestinal limbs than the conventional reconstructionedicine from ClinicalKey.com by Elsevier on February 18, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
Figure 2 At the preoperative and postoperative 3, 6, 9 and
12 months levels of hemoglobin, BMI and albumin
(mean  standard error). (a) Hemoglobin (g/dL), (b) BMI (kg/
m2), (c) Albumin (g/dL).
Table 3 Glycemic outcomes at 12 months after surgery by
surgery type.
Conventional
Billroth II
Long-limb
Roux-en Y
Fisher’s
exact
test
p-value
n, mean (SD) n, mean (SD)
Glycemic outcomea
Unchanged 55 (57.3) 53 (40.8)
Improvement 40 (41.7) 62 (47.7) <0.0012
Partial remission 1 (1.0) 4 (3.1)
Complete
remission
0 (0.0) 11 (8.5)
FBS, fasting blood sugar.
a Improvement was defined as reduction in the HbA1c and FBS
levels not meeting the criteria for remission but showing a
decrease in the antidiabetic medication requirements; partial
remission was defined as sub-diabetic hyperglycemia (FBS level,
100e125 mg/dL; HbA1c level, 6e6.4%) in the absence of anti-
diabetic medications; complete remission was defined as
normal measures of glucose metabolism (HbA1c level, <6%; FBS
level, <100 mg/dL) in the absence of antidiabetic medications.
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showed remarkably better outcomes in the long-limb group
than the conventional group for up to one year after the
operation.
One meta-analysis found that 78.1% of diabetic obese
patients experienced complete resolution after bariatric
surgery.24 In another meta-analysis of non-obese diabetic
patients (body mass index <30 kg/m2) with type II DM,
61.8% of patients were off medication after bariatric
surgery.25 Also, Lanzarini et al. from Chile reported that
65.2% (15/23) of non-morbidly obese (BMI < 35 kg/m2)Downloaded for Anonymous User (n/a) at Yonsei University College o
For personal use only. No other uses without permissiondiabetes patients with gastric cancer experienced remis-
sion and 30.4% (7/23) saw improvement after gastrectomy
with Roux-en-Y reconstruction.26 Our study, however,
found a complete remission rate of only approximately
10%, and more than 42% of the patients showed no gly-
cemic control change. There are several reasons for this
difference in remission rate. The first possible explana-
tion is that the mean age of our gastric cancer patients,
about 60 years, is higher than that in the pure bariatric
surgery group. Further, their diabetes duration was
longer, and their pancreatic beta cell function could be
poorly preserved. Second, we performed subtotal gas-
trectomy with fundus preservation, allowing our patients
with gastric cancer to ingest enough food after a period.
In contrast, fundus exclusion is the key procedure in pure
bariatric surgery, including Roux-en-Y gastric bypass.
Third, our patients with gastric cancer had relatively
lower BMI and weight loss, possibly weakening the meta-
bolic effect in our procedure compared to pure bariatric
surgery. Finally, there were differences in the ethnic
background of the patients.
However, the present study showed promising onco-
metabolic surgical results for patients with early gastric
cancer and type II diabetes. To obtain future perspectives,
a large-scale multicenter study with long-term outcomes is
needed. Additionally, an appropriate proximal intestinal
length for the bypass should be established.
The limitation of our study is that results from patients
who underwent long-limb Roux-en-Y bypass reconstruction
were compared with those who underwent conventional
Billroth II bypass reconstruction. So, we could not tell
whether the increased length of limbs made a difference or
whether Roux-en-Y itself made a difference.
In summary, onco-metabolic surgery could produce a
favorable prognosis for patients with type II diabetes and
gastric cancer. Basic mechanism studies of pure metabolic
effects for subjects with non-morbid obesity are needed to
explore this possibility. We should also investigate andf Medicine from ClinicalKey.com by Elsevier on February 18, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
Table 4 Logistic regressions for the improvement of diabetes control after 1 year according to surgery type and pre-operation
conditions.
Univariate Model Multivariate Model
OR 95% CI OR 95% CI
Surgery type
Conventional Billroth II Reference e Reference e
Long-limb Roux-en-Y 1.95 (1.14e3.33) 1.97 (1.14e3.42)
Sex
Women Reference e Reference e
Men 1.18 (0.63e2.20) 0.84 (0.42e1.65)
Age (year) 0.99 (0.96e1.02) 1.00 (0.97e1.03)
Diabetes duration
0e9 year Reference e Reference e
10 years 0.72 (0.41e1.27) 0.77 (0.41e1.43)
Missing 1.37 (0.53e3.54) 1.61 (0.60e4.35)
Preoperative FBS level 1.00 (0.99e1.00) 1.00 (0.99e1.01)
Preoperative HbA1c level 1.00 (0.82e1.22) 1.01 (0.80e1.29)
Preoperative BMI 1.09 (1.00e1.19) 1.09 (1.00e1.19)
OR, odds ratio; CI, confidence interval; BMI, body mass index; FBS, fasting blood sugar; HbA1c, Hemoglobin A1c.
302 J.-H. Kim et al.develop more criteria to predict favorable metabolic out-
comes for selective applications of this method.
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